Patricia M LoRusso

Trials

Studies that name Patricia M LoRusso as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:24 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT05053971 · Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

  National Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma · principal investigator
• Ph1
  NCT03925428 · Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

  National Cancer Institute (NCI) · withdrawn · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma · principal investigator
• Ph2
  NCT03878095 · Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

  National Cancer Institute (NCI) · active not recruiting · Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm · principal investigator
• Ph2
  NCT03212274 · Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

  National Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma · principal investigator
• Ph2
  NCT02849496 · Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

  National Cancer Institute (NCI) · active not recruiting · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma · principal investigator
• Ph1
  NCT01163071 · A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

  Celgene · terminated · Advanced Solid Tumors · principal investigator
• Ph1
  NCT00576654 · Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

  National Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma · principal investigator
• N/A
  NCT00369109 · Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

  Barbara Ann Karmanos Cancer Institute · completed · Breast Cancer, Colorectal Cancer, Pancreatic Cancer · study chair
• Ph1
  NCT00352443 · S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

  SWOG Cancer Research Network · completed · Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
• Ph2
  NCT00002585 · Pyrazoloacridine in Treating Women With Metastatic Breast Cancer

  Barbara Ann Karmanos Cancer Institute · completed · Breast Cancer · study chair
• Ph1
  NCT00002923 · KRN5500 in Treating Patients With Metastatic Solid Tumors

  Barbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
• Ph1
  NCT00003250 · Fenretinide in Treating Patients With Solid Tumors

  Barbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
• Ph1
  NCT00028548 · XK469 in Treating Patients With Advanced Solid Tumors

  Barbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.
  UH2CA271205 · NCI · YALE UNIVERSITY · fiscal years 2025 to 2026 · $210,089 awarded in 2026
  Same name and institution; not confirmed by an ID
• Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials Consortium
  UM1CA186689 · NCI · YALE UNIVERSITY · fiscal years 2014 to 2026 · $2,075,171 awarded in 2026
  Grant number is on one of their registry trials
• Early Clinical Trials of New Anti-Cancer Agents
  U01CA062487 · NCI · WAYNE STATE UNIVERSITY · fiscal years 1996 to 2013 · $620,359 awarded in 2013
  Grant number is on one of their registry trials
• Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus Irinotecan
  R21CA135572 · NCI · WAYNE STATE UNIVERSITY · fiscal years 2008 to 2009 · $338,176 awarded in 2009
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• North American Star Consortium
  UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026
  Named on NCT02849496
• NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
  UM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019
  Named on NCT02849496
• Texas EXperimental Cancer Therapeutics Network - TEX CTN
  UM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026
  Named on NCT02849496
• The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
  UM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026
  Named on NCT02849496
• Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
  UM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026
  Named on NCT02849496, NCT00576654
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 2008 to 2013
  Named on NCT00576654
• Cancer Research Training and Education Coordination
  P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Morhaf Al Achkar · fiscal years 2007 to 2026
  Named on NCT00369109, NCT00002585, NCT00002923, NCT00003250, NCT00028548
• Southwest Oncology Group Treatment Grant
  U10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 2008 to 2013
  Named on NCT00352443